Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.00 | 31.90 | 0.36% |
| CAC 40 | 8,138.94 | 73.92 | 0.92% |
| DAX 40 | 25,575.01 | 270.95 | 1.07% |
| Dow JONES (US) | 52,048.83 | 366.19 | 0.71% |
| FTSE 100 | 10,739.01 | 79.88 | 0.75% |
| HKSE | 25,048.76 | 6.05 | 0.02% |
| NASDAQ | 27,122.09 | 599.55 | 2.26% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,875.48 | 54.28 | 0.39% |
| S&P 500 | 7,764.70 | 114.20 | 1.49% |
| S&P/ASX 200 | 8,757.80 | 25.90 | 0.30% |
| SSE Composite Index | 3,945.42 | 4.49 | -0.11% |